Becton, Dickinson and Company $BDX Stock: ProShare Advisors LLC Boosts Holdings

ProShare Advisors LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,119,563 shares of the medical instruments supplier’s stock after purchasing an additional 47,184 shares during the period. ProShare Advisors LLC’s holdings in Becton, Dickinson and Company were worth $200,402,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vise Technologies Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $814,000. Cidel Asset Management Inc. raised its position in shares of Becton, Dickinson and Company by 3.0% during the 3rd quarter. Cidel Asset Management Inc. now owns 3,219 shares of the medical instruments supplier’s stock valued at $576,000 after buying an additional 95 shares in the last quarter. Avestar Capital LLC bought a new position in Becton, Dickinson and Company during the third quarter valued at approximately $332,000. International Assets Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at $16,110,000. Finally, Brian Low Financial Group LLC raised its position in Becton, Dickinson and Company by 5.5% in the 3rd quarter. Brian Low Financial Group LLC now owns 9,357 shares of the medical instruments supplier’s stock worth $1,675,000 after purchasing an additional 486 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 6,907 shares of company stock valued at $1,269,128. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Down 0.4%

BDX opened at $197.48 on Friday. The firm has a 50-day simple moving average of $186.58 and a two-hundred day simple moving average of $170.26. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $200.47. The company has a market capitalization of $54.41 billion, a PE ratio of 59.48, a price-to-earnings-growth ratio of 13.34 and a beta of 0.21. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the business posted $3.68 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a report on Friday, August 7th. UBS Group started coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective on the stock. Barclays initiated coverage on Becton, Dickinson and Company in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 target price for the company. Wolfe Research started coverage on Becton, Dickinson and Company in a research report on Tuesday, October 20th. They set an “outperform” rating for the company. Finally, Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.